taccalonolide-aj and Kidney-Neoplasms

taccalonolide-aj has been researched along with Kidney-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for taccalonolide-aj and Kidney-Neoplasms

ArticleYear
Development of Taccalonolide AJ-Hydroxypropyl-β-Cyclodextrin Inclusion Complexes for Treatment of Clear Cell Renal-Cell Carcinoma.
    Molecules (Basel, Switzerland), 2020, Nov-27, Volume: 25, Issue:23

    Microtubule-targeted drugs are the most effective drugs for adult patients with certain solid tumors. Taccalonolide AJ (AJ) can stabilize tubulin polymerization by covalently binding to β-tubulin, which enables it to play a role in the treatment of tumors. However, its clinical applications are largely limited by low water solubility, chemical instability in water, and a narrow therapeutic window. Clear-cell renal-cell carcinoma (cc RCC) accounts for approximately 70% of RCC cases and is prone to resistance to particularly targeted therapy drugs.. we prepared a water-soluble cyclodextrin-based carrier to serve as an effective treatment for cc RCC.. the AJ-HP-β-CD complex developed in this study may prove to be a novel tubulin stabilizer for the treatment of cc RCC. In addition, this drug delivery system may broaden the horizon in the translational study of other chemotherapeutic drugs.

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Cycle; Cell Movement; Cell Proliferation; Excipients; Humans; Kidney Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Steroids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2020